• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Athira Pharma Inc.

    7/1/25 7:37:16 PM ET
    $ATHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ATHA alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001604834
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    ATHIRA PHARMA, INC.
    SEC File Number
    001-39503
    Address of Issuer
    18706 NORTH CREEK PARKWAY, SUITE 104
    BOTHELL
    WASHINGTON
    98011
    Phone
    (425) 620-8501
    Name of Person for Whose Account the Securities are To Be Sold
    Mark James Litton
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer
    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    38th Fl.
    New York � NY � 10004
    2512373743904244507/01/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common06/30/2025Restricted Stock Lapse - See RemarksAthira Pharma, Inc.Checkbox not checked10833407/01/2025Equity Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Shares sold to cover tax obligation from settlement of vested Restricted Stock Units.
    Date of Notice
    07/01/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Mark Worthington, Attorney-in-Fact for Mark Litton

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $ATHA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ATHA

    DatePrice TargetRatingAnalyst
    9/19/2024$5.00 → $0.50Outperform → Neutral
    Mizuho
    9/4/2024Buy → Neutral
    Rodman & Renshaw
    9/4/2024Buy → Neutral
    BTIG Research
    9/4/2024Mkt Outperform → Mkt Perform
    JMP Securities
    8/19/2024$22.00Buy
    Rodman & Renshaw
    10/17/2022$20.00Mkt Perform → Mkt Outperform
    JMP Securities
    7/7/2022$6.00Buy
    Mizuho
    6/23/2022$36.00 → $5.00Buy → Hold
    Stifel
    More analyst ratings

    $ATHA
    SEC Filings

    See more
    • SEC Form 144 filed by Athira Pharma Inc.

      144 - Athira Pharma, Inc. (0001620463) (Subject)

      7/1/25 7:37:16 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by Athira Pharma Inc.

      144 - Athira Pharma, Inc. (0001620463) (Subject)

      7/1/25 7:36:09 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by Athira Pharma Inc.

      144 - Athira Pharma, Inc. (0001620463) (Subject)

      7/1/25 7:33:12 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATHA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Romano Kelly A bought $100,051 worth of shares (42,400 units at $2.36), increasing direct ownership by 111% to 80,715 units (SEC Form 4)

      4 - Athira Pharma, Inc. (0001620463) (Issuer)

      6/25/24 7:21:55 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Perceptive Advisors Llc bought $1,462,895 worth of shares (605,686 units at $2.42) (SEC Form 4)

      4 - Athira Pharma, Inc. (0001620463) (Issuer)

      12/29/23 5:24:55 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATHA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Fluke John M Jr

      4 - Athira Pharma, Inc. (0001620463) (Issuer)

      6/3/25 5:37:07 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Panzara Michael A.

      4 - Athira Pharma, Inc. (0001620463) (Issuer)

      6/3/25 5:36:21 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Romano Kelly A

      4 - Athira Pharma, Inc. (0001620463) (Issuer)

      6/3/25 5:35:41 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATHA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit

      Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical development On-track to enable initiation of a clinical trial in ALS patients in late 2025 BOTHELL, Wash., May 13, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that the Company will present data from a Phase 1 clinical trial of ATH-1105 in healthy volunteers at the 4th Annual ALS drug Development Summit taking place from May 1

      5/13/25 11:00:00 AM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates

      Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS); full healthy volunteer data expected in 2H25 On-track to enable dosing ALS patients in late 2025 BOTHELL, Wash., May 09, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended March 31, 2025, and provided recent pipeline and business updates. "We continue to focus our efforts on advancing ATH-1105 as a potential therapy for ALS. ATH-1105 has shown encouraging ev

      5/9/25 4:05:00 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates

      Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS) On-track to enable dosing ALS patients in 2025 BOTHELL, Wash., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the year ended December 31, 2024, and provided recent pipeline and business updates. "We look forward to the opportunity to continue to advance ATH-1105 as a potential therapy for ALS, which in various preclinical models has demonstrated a consistent ability to

      2/27/25 4:05:00 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATHA
    Leadership Updates

    Live Leadership Updates

    See more
    • Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer

      BOTHELL, Wash., April 15, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Javier San Martin, M.D., as Chief Medical Officer. Dr. San Martin brings more than 25 years of drug development experience and a proven track record leading cross-functional product teams to drive global development and commercialization strategies for multiple drugs across large and rare diseases with significant unmet medical need. "We are pleased to welcome Javier to the team and are confident his insights and guidance will be i

      4/15/24 7:00:00 AM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer

      BOTHELL, Wash., May 22, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Andrew Gengos as Chief Financial Officer and Chief Business Officer, effective immediately. Mr. Gengos replaces Glenna Mileson, who is retiring after serving as Athira's Chief Financial Officer for eight years. "On behalf of the entire Athira team, we thank Glenna for her many years of service, particularly for her stewardship during our transition to a publicly traded company, and wish her well in retirement," said Mark Litton, Ph.D

      5/22/23 7:00:00 AM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ric Kayne Publishes Investor Presentation Highlighting Urgent Need for Changes to Athira's Board of Directors

      New, Independent, Shareholder-Centric Directors are Needed to Ensure ATH-1017's Significant Potential is Realized and Reverse Destruction of Shareholder Value by Athira's Current Board Launches Campaign Website with Additional Information for Shareholders: www.SaveAthira.com Urges Athira Shareholders to VOTE their BLUE Proxy Card TODAY Richard A. (Ric) Kayne, who together with his affiliates beneficially owns approximately 4.8% of the outstanding shares of common stock of Athira Pharma, Inc. (NASDAQ:ATHA) ("Athira" or the "Company"), today released a detailed presentation to Athira's shareholders demonstrating the need for immediate change on the Company's Board of Directors (the "Board"

      4/25/22 8:00:00 AM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATHA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Athira Pharma Inc.

      SC 13G/A - Athira Pharma, Inc. (0001620463) (Subject)

      11/14/24 4:17:23 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Athira Pharma Inc.

      SC 13G - Athira Pharma, Inc. (0001620463) (Subject)

      11/7/24 1:15:00 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Athira Pharma Inc.

      SC 13D/A - Athira Pharma, Inc. (0001620463) (Subject)

      10/31/24 4:16:28 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATHA
    Insider purchases explained

    Analytical look into recent insider purchases

    See more
    • Breaking: Stock Acquired at Athira Pharma Inc. on Jun 25

      Recently, on June 25, 2024, Director Romano Kelly A bought $100,051 worth of shares in Athira Pharma Inc. This transaction involved acquiring 42,400 units at $2.36 per share, resulting in a significant increase in direct ownership by 111% to 80,715 units. The purchase was disclosed in the SEC Form 4 filing. Insider buying is often considered a bullish signal as insiders may have insights into the company's future performance. It's essential to analyze this insider purchase in conjunction with previous insider transactions to identify any patterns or trends. Taking into account the information from the SEC filings, several other insiders at Athira Pharma Inc. have also been active in the sto

      6/26/24 3:07:15 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATHA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Athira Pharma downgraded by Mizuho with a new price target

      Mizuho downgraded Athira Pharma from Outperform to Neutral and set a new price target of $0.50 from $5.00 previously

      9/19/24 7:34:53 AM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Athira Pharma downgraded by Rodman & Renshaw

      Rodman & Renshaw downgraded Athira Pharma from Buy to Neutral

      9/4/24 8:27:09 AM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Athira Pharma downgraded by BTIG Research

      BTIG Research downgraded Athira Pharma from Buy to Neutral

      9/4/24 7:28:38 AM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATHA
    Financials

    Live finance-specific insights

    See more
    • Athira Pharma Reports Full Year 2021 Financial Results and Provides Clinical Update

      On track to report topline data from ACT-AD Phase 2 Alzheimer's disease study in 2Q22 Expect to complete enrollment in LIFT-AD Phase 3 Alzheimer's disease study in 3Q22 Conference call today at 4:30 pm Eastern time BOTHELL, Wash., March 24, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the company's financial results for the year ended December 31, 2021 and provided a clinical update. "We entered 2022 with strong momentum from the solid foundation established throughout 2021 and have made considerable progress across

      3/24/22 4:05:00 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Athira Pharma to Host Fourth Quarter and Full Year 2021 Financial Results and Business Update Conference Call on March 24, 2022

      BOTHELL, Wash., March 17, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced it will report financial results for the fourth quarter and full year ended December 31, 2021 and provide a business update on Thursday, March 24, 2022 following the close of the U.S. financial markets. Athira will host a conference call to discuss these results on Thursday, March 24, 2022 at 4:30 pm Eastern time (1:30 pm Pacific time). In order to participate in the conference call, please dial 833-614-1520 (domestic) or 516-575-8710 (internationa

      3/17/22 7:00:00 AM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Athira Pharma Announces Leadership Changes; Mark Litton, Ph.D., M.B.A. Named President and Chief Executive Officer; Rachel Lenington, M.B.A. Named Chief Operating Officer

      Special Committee of the Board of Directors has concluded its investigation of Dr. Leen Kawas's Doctoral ResearchConference call to be held October 21, 2021 at 4:30 pm ET BOTHELL, Wash., Oct. 21, 2021 (GLOBE NEWSWIRE) --  Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the appointment of Mark Litton, Ph.D., M.B.A. as Chief Executive Officer of Athira. Dr. Litton succeeds Dr. Leen Kawas, who has resigned from her position as the Company's President and Chief Executive Officer and as a member of the Company's Board of Directors. Dr. Litton will also

      10/21/21 4:05:00 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care